Topic: Dementias and Neurodegenerative Diseases Research Network
Conditions
Interventions
Patients will have baseline mini-mental state examination and neuropsychological tests for specific occipito-parietal functions. Patients will be randomised to receive donepezil 5 mg or placebo once d
Sponsors
University College London (UCL) (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Clinical diagnosis of posterior variant of Alzheimer's disease 2. Memory test score above the 5th percentile on neuropsychological assessment 3. Absence of other causes of cognitive impairment based on dementia screen investigations available 4. Male and female, lower age limit of 18 years
Exclusion criteria
Exclusion criteria: 1. Significant neurological or psychiatric disease other than Alzheimer's disease 2. Significant systemic disease 3. Medications with the potential to affect cognition unless maintained on a stable dose for at least 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mini Mental State Examination, measured at 0 weeks and 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Digit span 2. Letter cancellation speed test 3. Simple calculation test 4. VOSP dot counting test 5. VOSP number location test | — |
Countries
United Kingdom
Outcome results
None listed